On Wednesday, Biocept Inc (NASDAQ:BIOC)’s shares declined -6.33% to $2.81.
Biocept Inc (BIOC) stated financial results for the three months ended March 31, 2015.
Recent Business Highlights
Expanded the Company’s non-small cell lung cancer (NSCLC) diagnostic capabilities to comprise biomarkers for EGFR mutations to assist in optimizing therapy for patients with NSCLC, adding to ALK and ROS1 biomarkers which were launched earlier this year.
Declared a partnership with the University of California, San Diego Moores Cancer Center with the aim of demonstrating the clinical utility of the Company’s technology to detect and identify biomarkers in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from blood samples of patients with NSCLC.
Launched the c-MET amplification detection test, which assists physicians in identifying patients who may be receptive to certain gastric and NSCLC treatments.
Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample.
Flamel Technologies S.A. (ADR) (NASDAQ:FLML)’s shares dropped -6.31% to $16.77.
Flamel Technologies S.A. (ADR) (FLML) will release financial results for the first quarter of fiscal year 2015 on Friday, May 15, 2015, before the market open. A conference call to talk about these results has been planned for Friday, May 15th at 10:00 a.m. ET. A question and answer period will follow administration’s prepared remarks.
Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology primarily in the United States and Europe.
At the end of Wednesday’s trade, Vuzix Corporation (NASDAQ:VUZI)‘s shares dipped -6.31% to $5.79.
Vuzix Corporation (VUZI) stated its first quarter 2015 financial results for the period ended March 31, 2015.
Vuzix stated $809,155 in revenues for the three months ended March 31, 2015 as contrast to $798,418 for the same period in 2014. This enhance was achieved despite the planned phasing out of the Company’s Wrap products and lower revenues from engineering services. We stated a net loss of ($5,090,852) for the three months ended March 31, 2015 as compared to a net income of $1,511,906 for the same period in 2014. The loss for the three months ended March 31, 2015 was primarily driven by about $2,100,000 in non-cash charges for stock and warrant compensation expense and a ($1,003,427) loss on mark to market derivative liability valuations as compared to a $2,575,262 gain in the preceding year’s first quarter.
Vuzix Corporation designs, manufactures, markets, and sells wearable display devices in the United States and internationally. The company’s products are worn like eyeglasses that enable the user to view video and digital content, such as movies, computer data, the Internet, or video games through various mobile electronic devices, such as cell phones, laptop computers, tablets, portable media players, and gaming systems.
TRANSFORM LOGIC CORP (OTCMKTS:TLOG), ended its Wednesday’s trading session with -6.30% loss, and closed at $2.53.
TRANSFORM LOGIC CORP (TLOG) declared termination of the underwriting agreement for and cancellation of its formerly declared underwritten public offering of 6.25 million shares of the Company’s common stock at a price to the public of $4.00 per share.
William Blair & Company, L.L.C. and Nomura Securities International, Inc. were joint book-running managers for the cancelled offering. WBB Securities was serving as the co-manager for the offering.
This offering was being conducted following a shelf registration statement that was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on January 15, 2015.
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. Its clinical-stage product candidate, Birinapant, is in Phase II clinical trial administered with azacitidine for the treatment of myelodysplastic syndromes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
